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Summary Low expression of the antimetastatic gene nm23 has been associated with shorter overall survival in breast cancer. To better
understand the mechanism(s) of action of this protein, we compared the levels of the nm23 protein in 152 breast cancer samples with other
factors known to be involved in metastasis or related to prognosis. There was no significant relationship between either of the nm23 isoforms
and cathepsin D (Cat-D), urokinase plasminogen activator (uPA), its inhibitor (PAI-1), steroid hormone receptors or ploidy status. A marginal
inverse correlation was observed between per cent S-phase and nm23-H1 expression (r= - 0.193, P= 0.047) and a positive correlation was
observed between uPA receptor (uPAR) and both nm23-H1 (r= 0.263, P= 0.0018) and nm23-H2 (r= 0.230, P= 0.0064). The nm23-H1 gene
was transfected into MDA-MB-231 human breast cancer cells and 12 clones were selected, of which two were characterized extensively. We
found no significant differences in Cat-D, uPA, PAI-1 or uPAR, as a function of nm23 expression in either the MDA-MB-231 cells or the
transfected clones. Compared with the parent cell line, we did observe a dose-dependent decrease in growth factor-stimulated motility and a
decrease in metastatic potential in two clones with four- and eighffold elevated nm23-H1 expression, whereas the proliferative activities were
similar. We conclude that the decreased metastatic potential might be related to down-regulation of growth factor-stimulated motility.
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The genotypic alterations that accompany and/or determine the
metastatic phenotype ofcancer cells are not well characterized, but
metastatic progression is thought to involve the accumulation of
functionally additive genetic defects (Liotta and Steeg, 1991;
Stracke and Liotta, 1992).
A specific gene family related to non-metastatic invasiveness of
cancer was first characterized in 1988 and called nm23. This gene
was identified using differential hybridization techniques in
K1735 murine melanoma clones having different metastatic
potentials (Steeg et al, 1988). The first member of the family,
nm23-HJ, has demonstrated antimetastatic properties in animal
models (Leone et al 1991, 1993), and levels ofnm23-H1 protein or
RNA have shown an inverse correlation with lymph node status
and patient survival in a number of human breast cancer studies
(Bevilacqua et al, 1989; Barnes et al, 1991; Hennessy et al, 1991;
Hirayama et al, 1991; Royds et al, 1993). A second member ofthis
family, nm23-H2 (Stahl et al, 1991), encodes for a protein that has
88% homology to nm23-H1. Finally, a third member of this
family, Dr-nmn23, has been isolated and shows a 65% homology to
the other members and contains several of the key domains. This
protein is found to be increased in leukaemia blast crisis and
inhibits differentiation and induces apoptosis (Venturelli et al,
1995). Whereas the preponderance of evidence suggests that
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nm23-H1 protein expression is related to lymph node metastasis
and patient survival, there is still some controversial data that
dispute the role of nm23 expression levels as predictive of nodal
involvement and breast cancer patient survival (Goodall et al,
1994; Sawan et al, 1994; Russell et al, 1997). Correlation between
nm23-HI levels and prognosis of a number of other tumour types
has also been demonstrated (De La Rosa et al, 1995).
No clear molecular mechanism of action that explains the
antimetastatic role of nm23 has been demonstrated so far.
Transfection ofthe nm23-HJ gene in MDA-MB-435 breast cancer
cells has been associated with reduced motility in response to
growth factors (Kantor et al, 1993) and the development of ducts
in vitro (Howlett et al, 1994). These observations suggest a role for
nm23-H1 in motility responsiveness and tissue development. The
nm23-HI and nm23-H2 proteins are identical to the nucleoside
diphosphate kinase (NDPK) A and B respectively (Gills et al,
1991). The kinase activity, however, has been dissociated from the
antimetastatic role of nm23 (Leone et al, 1993; Sastre-Garau et al,
1992). The nm23-H2 protein has been identified as the human PuF
factor (Ji et al, 1994; Postel, 1996), which is a transcriptional acti-
vator of the c-mvc proto-oncogene. Although there has not been a
positive correlation between the levels of expression of nm23-H2
and metastatic potential, very few studies have been performed to
address this issue.
The urokinase pathway of plasminogen activation and other
proteolytic enzyme systems are thought to be involved in extracel-
lular matrix degradation, facilitating tumour invasion and metas-
tasis (Rochefort, 1990; Ossowski, 1992; Christensen et al, 1996).
Additionally, the production of plasmin through the uPA cascade
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has been associated with the activation of latent metalloproteases
and the regulation of certain growth factors (Sato and Rifkin,
1989; Lyons et al, 1990; Campbell et al, 1992). A number of
studies have shown that patient survival is independently associ-
ated with the levels of proteolytic enzymes, their receptors and
inhibitors (Duffy et al, 1990; Rochefort 1990; Kute et al 1992,
1997; Gr0ndahl-Hansen et al., 1993; Janicke et al., 1993; Foekens
etal., 1994; 1997).
This study was undertaken to evaluate the relationship between
the levels ofnm23 (H1 and H2) and uPA, uPAR, PAI-1 and Cat-D as
a means of defining a biological mechanism for the antimetastatic
effect of these nm23 isoforms. The levels of these isoforms were
also compared with other cancer markers such as steroid receptors,
%S activity and ploidy status. Additionally, nm23-H1-transfected
breast cancer cells were used to evaluate any direct effect of nm23-
H1 expression on invasion-related factors, proliferation, growth
factor-stimulated motility and metastatic potential.
METHODS
Breast cancer tissue accrual and extraction
Human breast cancer tissue was acquired in a prospective manner
from 152 patients diagnosed with breast cancer. The evaluation of
various prognostic markers including nm23 was performed as part
of a routine breast cancer panel. Fresh tissue was acquired directly
from the operating room when surgery occurred in the hospital.
When the sample was transported from an external site, the fresh
tissue was transported on dry ice and immediately transferred to
- 70°C until the tests could be performed. The only restrictive basis
for selection of potential breast cancer tissues for inclusion in this
study was the presence of an adequate tissue sample following
routine breast cancer sample analyses (steroid hormone receptor
status, DNA index and cell cycle kinetics). As a quality control,
adjacent sections to all samples were analysed by standard haemo-
toxylin and eosin (H&E) histochemistry in order to verify tumour
tissue content. The fresh breast cancer tissues were processed for
biochemical steroid receptor analyses using standard tissue homoge-
nization and high-speed centrifugation techniques (Kute et al, 1992).
The resulting extract was analysed for total protein (Bio-Rad assay)
and the various markers as described below.
nm23 measurement
nm23-HI and nm23-H2 proteins were measured by a Western blot
analysis using a standard curve containing known quantities of
nm23-H1 and as described in detail previously (Russell et al,
1997). The detection limit was 250 pggIl-'. Breast tumour extracts
were analysed using SDS-PAGE electrophoresis and the levels of
nm23 were measured by densitometry from the standard curve run
concurrently with patient samples. A polyclonal antibody to nm23
was used. This antibody has been shown (Russell et al, 1997) to
have similar reactivity in Western blot analysis to the peptide 11
antibody described by Leone etal (1993). The polyclonal antibody
was a generous gift from Oncologix and recognizes both nm23-H1
and nm23-H2 by Western blot and immunohistochemical analyses
(Russell et al, 1997).
Cat-D, uPA, uPAR and PAI-1 measurement
The analysis of Cat-D was performed using a commercially
available radioimmunometric (RIA) kit (CIS Bio International,
Bedford, MA, USA) with triplicate measurements for each
sample (Kute et al, 1992). The detection limit was 31 pg ml'. The
urokinase plasminogen activator (uPA), its receptor (uPAR) and its
inhibitor (PAI-1) were measured using previously described
ELISA techniques (Gr0ndahl-Hansen et al, 1993; Rosenquist et al,
1993; R0nne et al 1995) with detection limits of 25 pg ml-',
16 pg ml-', and 25 pg ml-' respectively. In order to eliminate
sampling artefacts, uPA, PAI-1 and uPAR analyses were
performed using the same tissue extracts that had been previously
analysed for nm23 and Cat-D at our institution.
Additional breast cancer prognostic markers
The evaluation of oestrogen and progesterone receptors, DNA
ploidy and per cent S-phase was performed prospectively to deter-
mine the relationship between nm23 and these prognostic markers.
Steroid receptor status was performed using either standard
biochemical (Kute et al, 1992) or immunohistochemical methods
(Barnes et al, 1996). Tumours were considered steroid receptor
positive ifthey contained more than 10 fmol ofreceptor per mg of
protein or if the steroid receptor was present in more than 10% of
the tumour nuclei as seen in the immunohistochemistry procedure.
DNA ploidy status and per cent S-phase were evaluated using flow
cytometry (Kute et al, 1992) on fresh tissue. The percentage of
tumour cells in S-phase was determined using the ModfitTN' soft-
ware analysis program (Kute et al, 1992).
Characterization and transfection of MDA-MB-231-BAG
cells
The human breast cancer cell line, MDA-MB-231-BAG,
(containing a lacZ gene) was previously described and stains
positive for P-galactosidase when fixed in glutaraldehyde and
incubated overnight in X-gal staining reagent (Brunner et al,
1992). The BAG vector facilitated the detection of micro-
metastatic lesions in various tissues ofthe animals. Both H&E and
X-gal staining were performed on all lungs and suspicious growths
when examining the mice for metastatic disease.
The MDA-MB-231-BAG cells were transfected with the cDNA
for nm23-H1 (kindly provided by Dr PS Steeg), which was inserted
into the multiple cloning site of the delta pCEP4 vector using
BamHI and XhoI restriction enzymes. This vector contains the
hygromycin selectable marker and uses the CMV early promoter to
drive transcription ofthe inserted sequence. This vector was modi-
fied by the deletion of the EBNA and ori-O sequence to prevent
episomal replication and thus force integration of the vector into
chromosomal DNA (Bunting and Townsend, 1996). The transfec-
tion was performed using standard calcium phosphate precipitation
techniques and the successfully transfected clones were selected in
0.67 mg ml-' hygromycin-containing medium. The dose of
hygromycin chosen for selection was 99.9% cytotoxic to the
parental cell line using clonogenic assays. Twelve clones were
selected, two of which contained four (clone 40) and eight (clone
47)-fold elevated levels of nm23 when compared with the parental
cells that contained 0.173 ± 0.047 ng jig-I nm23-H1 protein as
determined by Western blot analyses.
The cell pellets of the MDA-MB-231-BAG cells and nm23-Hl
transfected clones were homogenized manually using 20 strokes in
a ground glass mortar and pestle apparatus. All subsequent
analyses for Cat-D, uPA, uPAR and PAI-I expression were
performed as described for the breast tumour samples.
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Table 1 Description of parameters used in the study
Parameter n Median Mean ± s d Range
% S-phase 110 12.0 14.04 ± 9.37 0-36.00
% G, phase 110 81.0 79.5 + 11.23 51-97
nm23-H1a 147 0.44 0.57 + 0.48 0-2.77
nm23-H2a 147 0.30 0.42 + 0.34 0-2.00
Cathepsin Db 150 45.3 51.40+ 2.41 5.06-173.10
PAI-1c 144 0.96 2.20 ± 0.26 0-22.37
uPA-Rc 144 0.92 1.40 + 0.19 0-21.70
uPAc 144 0.75 1.38 +0.20 0-19.48
ang pg-1 protein. bpmol mg-' protein. cng mg-' protein.
The measurement of in vitro proliferation of MDA-MB-23I -
BAG-and MDA-MB-231-BAG-nm23-H1-transfected clones was
performed by adding 0.4 million cells per flask and measuring the
cell number in triplicate over the course of 7 days (see Figure 2B).
Motility studies
The evaluation of the motility of MDA-MB-231-BAG cells and
the transfectants was performed without prior knowledge ofnm23-
H1 levels by Dr Kantor. Motility was assessed using a modified
Boyden chamber assay as previously described (Kantor et al,
1993). The growth factors used in this study were 0.5% serum,
lysophosphatidic acid (LPA) and platelet-derived growth factor
(PDGF). The concentrations of growth factors used are listed in
the legend to Figure 3.
Animal studies
Two sites on the hindquarters ofthe 6-week-old female athymic nude
mice (Balb/c purchased from Goodwin Institute forCancerResearch,
Plantation, FL, USA) were inoculated with 106 cells (MDA-MB-
231-BAG, clones 40 or 47) each. Ten animals were included in each
group. The tumours were allowed to grow for 32 days, at which time
the surviving animals were sacrificed. The in vivo growth of the
MDA-MB-231-BAG- and MDA-MB-231-BAG-nm23-H1-trans-
fected cells was assessed over the course of a 5-week period oftime
using two-dimensional analysis of each of two tumour sites on each
of ten animals. The mean tumour size was evaluated for the parent
and each ofthe two nm23-H1-transfected clones.
The lungs were removed from each animal and, during the
autopsy, any suspicious area was also collected. These tissues were
fixed with glutaraldehyde and then stained for 3-galactosidase
activity as previously described (Bruinner et al, 1992). Subsequently,
the tissues were formalin fixed and paraffin embedded. The analysis
ofthe mouse lungs and other suspicious growths was performed by a
pathologist (K Geisinger) using both H&E and X-gal-stained tissues.
Each lung or suspected tissue was analysed using a multilevel tech-
nique with a minimum of 3-4 levels (50,m apart) to enhance
the detection of micrometastatic disease. Any animal tissue that
contained tumour cells was defined as positive for metastasis.
Table 2 Relationship of nm23-H1 and nm23-H2 to steroid receptor status and ploidy
nm23-H1 (ng gg-' protein) nm23-H2 (ng jg-1 protein)
n Median Mean P-value Median Mean P-value
(s.d.) (s.d.)
ER- 77 0.456 0.540 0.290 0.404
(0.483) 0.48 (0.342) 0.48
ER+ 70 0.490 0.579 0.317 0.425
(0.485) (0.343)
PR- 84 0.510 0.579 0.299 0.420
(0.486) 0.60 (0.348) 0.65
PR+ 62 0.442 0.564 0.306 0.409
(0.488) (0.346)
Diploid 46 0.506 0.551 0.366 0.404
(0.345) 0.66 (0.244) 0.52
Aneuploid 94 0.445 0.618 0.296 0.441
(0.698) (0.494)
Table 3 Relationship of nm23-H1 and nm23-H2 to each other and to other prognostic markers
Factor nm23-H1 nm23-H2
n r-value P-value r-value P-value
nm-23-H1 (ng pg-1 protein) 147 0.751 0.0001
% S-phase 106 -0.193 0.047 -0.122 0.21
%G, phase 106 0.172 0.078 0.107 0.27
Cathepsin D (pmol mg-') 145 0.112 0.18 0.048 0.57
uPA (ng mg-' protein) 139 0.096 0.26 0.046 0.59
uPAR (ng mg-' protein) 139 0.263 0.0018 0.230 0.0064
PAI-1 (ng mg-' protein) 139 0.139 0.10 0.125 0.14
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Figure 1 Cell pellets were obtained from MDA-MB-231-BAG cells and each of 12 clones transfected with nm23-H1. The lysates were used to measure nm23-
Hi in relation to Cat-D (A), uPAR (B), uPA (C) and PAI-1 (D). The comparison between the levels of nm23-H1 expression and the expression of each of these
proteases and protease-related factors demonstrated no significant correlation
Statistical analyses
Relationships between nm23 isoforms and Cat-D, uPA, uPAR,
PAI- I, per cent S-phase, were evaluated using Spearman correla-
tion coefficients. The relationships involving nm23-Hl and nm23-
H2 with steroid receptor and DNA ploidy status were analysed
using the Wilcoxon ranked-sum statistics. Fisher's exact test was
used to assess difference in per cent metastatic potential in Table 3.
Analyses of the effect of nm23-Hl expression on motility were
performed using analyses of variance.
RESULTS
Assessment of the distribution of nm23-H and nm23-H2 protein
levels revealed a great deviation from normality. Both log and
square root transforms of the data did not improve the situation,
prompting use of non-parametric techniques in the analysis.
Descriptive statistics including the median, mean with standard
deviation and ranges for nm23-H1 and H2, per cent S-phase,
proteases (Cat-D, uPA), PAI- I and uPAR for this group of patients
are given in Table 1. The patient population exhibited a wide vari-
ability with respect to the levels of the markers analysed as would
be expected from a random, prospective analysis. The levels of
expression of the proteolytic factors are consistent with our
previous findings (Kute et al, 1998). Of the tumours analysed,
68% were aneuploid, 47% were oestrogen receptor positive and
42% were progesterone receptor positive (Table 2). The DNA
ploidy and steroid receptor status fall within the normal limits for a
breast cancer population.
Analyses ofthe correlation between the levels ofnm23 isoforms
and per cent S-phase, Cat-D, uPA, uPAR and PAI-I are shown in
Table 3. There was a strong correlation between the levels of
nm23-HI and H2 expression within a given tissue (r = 0.75, P=
0.0001). This observation is not surprising considering the co-
ordinate regulation of these two genes. There was no relationship
between the levels of nm23-HI or -H2 and the proteases Cat-D
and uPA, or the uPA inhibitor, PAI-1. Whereas there was a positive
direct correlation between both nm23-H and -H2 with uPAR
expression (r = 0.26, P = 0.0018, and r = 0.23, P = 0.0064, respec-
tively), the relatively low correlation coefficient values call the
biological relevance of these observations into question. As
elevated levels ofuPAR have been shown to have a poor prognosis
in breast cancer (Gr0ndahl-Hansen et al, 1995), the positive corre-
lation between uPAR and the antimetastatic gene nm23 was there-
fore unexpected. Although the magnitude was low, there was a
significant inverse relationship between nm23-H I and per cent S-
phase (r = - 0.19, P = 0.047). Using G, as an inverse of prolifera-
tion, a direct correlation was observed as one would expect (Table
2B). Further evaluation of the relationship between nm23-HI and
per cent S- and G, phases of aneuploid and diploid populations
was performed independently and did not improve the correlation
coefficient (data not shown).
The statistical analysis of the relationship between nm23-H
and -H2 levels with ER, PR and DNA ploidy is shown in Table 2.
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Figure 3 MDA-MB-231-BAG parent and clones 40 and 47 were analysed
for random (DMEM) and growth factor-stimulated motility using a modified
Boyden chamber assay. Results represent the mean of six measurements
from two independent experiments. *Results that were statistically different
from untransfected cells using analysis of variance
Table 4 Metastatic potential of MDA-MB-231-BAG and two nm23-H1
transfected clones
Group No. Lung mets Other mets Overall mets (%)
MDA-MB-231 parent 7 3/7 3/7 5/7 (71)
Clone 40 8 1/8 3/8 3/8 (38)
Clone 47 10 4/10 1/10 4/10 (40)
0
0 10 20 30 40
Time (days)
Figure 2 A MDA-MB-231-BAG cells and clones 40 and 47 (4 x 105) were
added to 25-cm2 flasks containing DMEM, 10% FCS, P/S, L-glutamine and
non-essential amino acids. Cells were harvested with 0.25% trypsin-versine
daily for 7 days and cells counted. B MDA-MB-231-BAG cells and clones 40
and 47 were injected into the hind quarters of athymic nude mice and the
resulting tumours were measured every 7-12 days for 32 days
These data demonstrate that there is no statistically significant
relationship between these parameters
To address further the relationship between the expression ofthe
Cat-D, uPA, uPAR and PAI-1, and nm23-Hl, the human breast
cancer cell line (MDA-MB-231-BAG) was transfected with the
modified cDNA for nm23-Hl (Leone et al, 1991).
Cell pellets ofthe 12 nm23-H 1-transfected clones were obtained
from log growth cells and cell extracts were analysed for the levels
ofCat-D, PAI-1, uPA and uPAR using the same methods as for the
breast tissue extracts. There was no significant relationship
between the level of expression of nm23-Hl and any of these
factors (Figure 1), although there was a trend towards high nm23-
HI expression in association with high Cat-D levels (r = 0.56, P =
0.058). These data thus support the observations described above
concerning the prospective breast cancer study, which suggests
that nm23-Hl levels are not highly related to the expression of
Cat-D, uPA, PAI- 1 or uPAR. As this comparison is using a pure
population of cancer cells, one would speculate that it would
correct for sampling artefacts that are always present when using
solid tumour tissues.
Of the 12 transfectants, two clones were selected (clone 40 and
47) that contained four- and eightfold elevated levels ofnm23-Hl,
respectively compared with the untransfected parental cell line,
which contained 0.173 ± 0.047 ng ,ug-I protein. These clones were
evaluated for proliferative activity with both in vitro and in vivo
systems and compared with the growth characteristics of the
parent cell line. The data are shown in Figure 2A and B. There was
no significant difference between the proliferation of clones 40
and 47 (high nm23-H1) and the proliferative rate of the untrans-
fected MDA-MB-231 BAG (parent) cells in tissue culture when
analysed daily for 7 days (Figure 2A). The injection of 106 cells
into the hindquarters of nude mice resulted in similar rates of
growth of MDA-MB-231-BAG parent and clones 40 and 47 as
determined by weekly two-dimensional measurements of tumour
size for 32 days (Figure 2B).
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We also performed studies in nude mice to determine whether
the MDA-MB-231-BAG cells transfected with nm23-HI showed
a reduced metastatic potential when compared with the parental
cell line, which expresses very low levels of nm23-H1. The
advantage of using the MDA-MB-231-BAG cells to detect the
metastatic lesions in nude mice is evident in that micrometastatic
lesions are easily detected when the excised mouse lungs have
been treated with the f-galactosidase substrate, X-gal. Whereas
the MDA-MB-435-BAG cells tend to produce large metastatic
foci in the lungs of nude mice (Brunner et al, 1992), the MDA-
MB-231-BAG cells produce very small foci that are not readily
detected by the eye.
Each nude mouse was injected with 106 MDA-MB-231-BAG
cells or MDA-MB-231-BAG-nm23-H1 clones into the hind
quarter. The tumours were allowed to grow (Figure 2B) for 32
days, at which time the animals were sacrificed. The lungs and any
visually suspicious growths were analysed for the presence of
metastatic cells. The data depicting the metastatic potential of the
nm23-transfected cells are shown in Table 4. These data demon-
strate that injection of the nude mice with the MDA-MB-231-
BAG-nm23-Hl clones resulted in between 40% and 44% fewer
animals developing metastases, compared with mice injected with
the untransfected cells. These preliminary data thus show a trend
that high expression of nm23 results in a lowering of the
metastatic potential of the cells. However, analysis of the data
using Fisher's exact test demonstrated that the groups were not
significantly different. During the period of tumour growth in
these animals, the control group lost three of ten animals, whereas
the transfected groups lost only 3 out of 20 animals. It is not
known why the control animals seemed to die prematurely as all
the animals were given the same amount of tumour burden at the
start. One of the animals in the transfected group could be used in
the metastatic potential analysis (Table 4).
The in vitro motility of the MDA-MB-231-BAG cells and
nm23-HI-transfected clones was investigated using a modified
Boyden chamber assay (Kantor et al, 1993). The results of theses
studies are summarized in Figure 3. Whereas there was no differ-
ence in random (unstimulated) motility between untransfected
MDA-MB-231-BAG cells and nm23-HI-transfected clones, there
was a significant reduction in growth factor [0.5% bovine calf
serum (BCS), 1 tg ml- lysophosphatidic acid (LPA) and
40 ng ml platelet derived growth factor (PDGF)]-induced
motility in the clones. The differences in growth factor-stimulated
motility are represented as the mean of six replicates performed in
two independent experiments. Figure 3 shows that the number of
cells migrating in response to LPA, PGDF and 0.5% serum
decreased in a dose-dependent manner as a function of nm23-H1
concentration. These data suggest a possible role for nm23-H1 in
the regulation ofmotility responsiveness to growth factor stimula-
tion. This effect on motility has been previously demonstrated in
the MDA-MB-435 breast cancer cell line (Kantor et al, 1993). Our
results confirm this important observation in a different breast
cancer cell line, indicating that down-regulation of motility by
nm23 in breast cancer tissues may be a necessary feature of the
biological mechanism of action of this protein.
DISCUSSION
The biological mechanism(s) by which nm23 attenuates metastatic
disease has not been clearly defined. The hypothesis that nm23-HI
may serve a role in the regulation of motility, proliferation,
proteases (uPA, and Cat-D), protease inhibitor (PAI-I) or protease
receptor (uPAR) expression was investigated in solid tumors and
in cells transfected with nm23-H1 to establish a role for nm23 in
metastasis suppression.
In 152 human breast tumour extracts, there was no relationship
between the levels of nm23-HI or -H2 and DNA ploidy, steroid
receptor status, proteases (Cat-D, and uPA) or PAI- 1. Analyses of
the relationship between the levels of nm23 isoforms and the
expression of uPAR showed a significant correlation. This obser-
vation was unexpected given that elevated levels of uPAR have
been associated with poor prognosis in breast cancer patients
(Gr0ndahl-Hansen et al, 1995), and elevated levels of nm23-Hl
have been associated with a good prognosis. Although this statis-
tical observation cannot be overlooked, it is difficult to explain
what the relationship between uPAR and nm23-Hl may be.
Expression of components of the uPA system have been localized
to different types of cells in breast cancer tissues and the expres-
sion level of these components seems to vary with tumour differ-
entiation (Christensen et al, 1996) Would this be a factor in how
these markers predict prognosis? In a recent retrospective study of
a small number of patients, nm23 and erbB-2 expression by
immunohistochemistry predicted disease-free survival in a
univariate analysis. Other factors such as cathepsin D and p53
were of borderline utility (Han et al, 1997). This is encouraging
but more studies need to be done. It is also very important to deter-
mine what method of analysis for these markers would yield the
best results. Prospective studies that investigate patient prognosis
would be especially useful in determining the clinical significance
ofthese markers. Our present studies are ongoing with this patient
population but the mean follow-up time at present is less than 2
years and would therefore not yield valid information at this time.
Although there was a statistically significant inverse relation-
ship between the levels of nm23-H1 and per cent S-phase in the
patient tumour population, the correlation was low and the in vitro
and in vivo MDA-MB-231-BAG clonal data suggest that nm23
expression is not related to proliferation. Yet a positive correlation
between per cent S-phase and nm23 RNA expression has been
shown in both breast cancer cell lines and solid tumours, using
RNA extraction, [3H]-thymidine labelling and flow cytometry
(Caligo et al, 1995). It is, therefore, possible that the relationship
between nm23 and per cent S-phase is relevant and the analysis of
clonal populations for similar correlations is not representative of
the multiple factors that modulate proliferation in vivo. If this is
the case, only large prospective clinical studies can adequately
address this issue.
The role ofnm23 as a metastasis-suppressor gene is suggested in
the animal experiments where 40-50% fewer animals developed
metastases with the MDA-MB-231-BAG clones expressing
elevated levels of nm23-H1. Although not statistically significant,
these data are in general agreement with the observation by Leone
et al (1993) using the MDA-MB-435 human breast cancer. They
demonstrated a 78% reduction in metastatic lesions in animals
injected with the nm23-HI-transfected cell line compared with the
mock-transfected cells. The reasons as to why our results are less
pronounced are unknown except that we used a different cell line
and our protocols were different. Although it is hard to quantify the
amount of metastatic disease in the lungs using standard histolog-
ical analysis, we did find that the amount ofcancer cells in the lung
tissue was higher in the animals with the parental tumours than in
the animals with the nm23-transfected cells. Further studies need to
be performed to quantify the tumour load in these animals.
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The role of nm23-HI in suppressing growth factor-stimulated
motility is in line with the suggested antimetastatic mechanism of
action of nm23. The MDA-MB-435 breast cancer cell line exhib-
ited reduced response to motility-stimulating factors following
nm23-HI transfection (Kantor et al, 1993). Recently, site-directed
mutagenesis studies have identified critical amino acids required
for this motility responsiveness (MacDonald et al, 1996). This
study showed that mutation ofeither proline-96 to serine or serine-
120 to glycine, caused MDA-MB-435-wtHl-transfected cells to
revert to parental levels of motility responsiveness to 0.5% serum
or autotaxin. Recent studies also using site-directed mutagenesis
of serine-120 and proline-96 have attributed a biological mecha-
nism for the abrogation ofmotility suppression by these mutations
(Freije et al, 1997). The analyses of purified nm23 mutants of
proline-96 and serine-120 demonstrated alterations in autophos-
phorylation and histidine kinase activity (Freije et al, 1997). The
combined observations ofMacDonald et al and Freije et al suggest
a biological link between motility responsiveness and structure
and function of nm23-H 1. Freije et al propose that metastatic
potential may be related to protein histidine kinase activity where
increased activity favours the non-metastatic state.
Three key events in the metastatic cascade (proteolysis of extra-
cellular matrix, motility and proliferation/colonization) have been
addressed in this study. The data suggest that only changes in
growth factor-stimulated motility is related to nm23-HI expres-
sion. We are currently investigating the possibility of a common
signal transduction pathway that is affected by the levels of nm23-
H I expression.
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